New combo therapy aims to stop liver cancer recurrence in High-Risk patients
NCT ID NCT05367687
First seen Nov 17, 2025 · Last updated Apr 28, 2026 · Updated 14 times
Summary
This study tested whether adding rivoceranib to camrelizumab (a type of immunotherapy) works better than camrelizumab alone to keep liver cancer from returning after surgery or ablation. It involved 251 patients with hepatocellular carcinoma at high risk of recurrence. The main goal was to see how long patients lived without their cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) AT HIGH RISK OF RECURRENCE AFTER CURATIVE RESECTION OR ABLATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.